ClinicalTrials.gg
CompletedNCT01906489Updated Jul 21, 2022Results posted

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Phase 2 interventional study of AKB-6548 and Placebo in Anemia and Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 47 sites in United States. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
10th of 27
210 · median 60
Started
2013
the only one that year
Phase 2
8 of 27
none open now
Registered
3rd of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 2, and was the 3rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.

03

Conditions studied

  • Anemia
  • Chronic Kidney Disease

Keywords

  • anemia
  • chronic kidney disease
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • kidney
  • oral anemia treatment
  • hemoglobin
  • hypoxia-inducible factor
  • HIF
  • hypoxia-inducible factor prolyl-hydroxylase inhibitor
  • HIF-PHI
  • efficacy
  • safety
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 to 82 years of age, inclusive
  • Chronic Kidney Disease with a category of G3a-G5 and not yet on dialysis
  • eGFR ≥ 10 and ≤ 65 mL/minute/1.73 m2
  • Anemia secondary to CKD with an ESA status and a Screening HGB as per protocol
  • Iron replete with ferritin and TSAT levels as defined per protocol

Key Exclusion Criteria:

  • > 44.0 kg/m2
  • Red blood cell transfusion within 11 weeks prior to the Screening visit
  • Androgen therapy within the previous 21 days prior to the Screening visit
  • Intravenous iron within the past 4 weeks prior to the Screening visit
  • or ALT >1.8x , alkaline phosphatase >2x ULN, or total >1.5x ULN
  • Screening with > 500 msec
  • Uncontrolled hypertension
  • Class III or IV congestive heart failure
  • Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to the Screening visit
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    AKB-6548

    Drug: AKB-6548

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

  • DrugPlacebo

    Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Successful Hemoglobin Response

    Hemoglobin (Hgb) response was defined as participants with mean Hgb ≥11.0 grams per deciliter (g/dL) (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving Erythropoiesis-Stimulating Agents (ESA) or transfusion.

    Time frame: Weeks 19 and 20

Secondary outcomes

  1. Percentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study

    Participants who have experienced an excursion in Hgb to ≥13.0 g/dL at any time during the study were considered as "failures". Data was presented for failures.

    Time frame: Up to 20 Weeks

  2. Percentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value

    Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing). Analysis of this secondary outcome measure is a reanalysis of the primary outcome measure whereby the response was determined solely by the Hgb value and receiving rescue therapy did not make the participant a failure.

    Time frame: Weeks 19 and 20

  3. Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group

    Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Treatment Naïve group, defined as participants who had never received treatment with an ESA and who had a screening Hgb level of ≤10.5 g/dL.

    Time frame: Weeks 19 and 20

  4. Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group

    Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Previously Treated group, defined as participants who had previously received ≥1 dose of an ESA, had been off of ESA therapy for ≥11 weeks at the time of screening, and had a screening Hgb level of ≤10.5 g/dL.

    Time frame: Weeks 19 and 20

  5. Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group

    Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Actively Treated group, defined as participants who had been actively treated with an ESA for a minimum of 4 months before screening, had received at least 2 doses within the last 4 months, had received their last dose within 6 weeks before screening, and had a screening Hgb level ≥9.5 g/dL and ≤12.0 g/dL.

    Time frame: Weeks 19 and 20

  6. Percentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population

    Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Analysis of this secondary outcome measure was performed in the mITT population.

    Time frame: Weeks 19 and 20

  7. Change From Baseline in Hemoglobin

    Blood samples were collected to assess Hgb. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hgb concentration increased.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  8. Absolute Values of Hemoglobin

    Blood samples were collected at indicated time points for analysis of hemoglobin

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  9. Change From Baseline in Hematocrit

    Blood samples were collected to assess Hematocrit. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hematocrit concentration increased.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  10. Absolute Values of Hematocrit

    Blood samples were collected at indicated time points for analysis of Hematocrit.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  11. Change From Baseline in Red Blood Cell Count

    Blood samples were collected to assess red blood cell count. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated red blood cell count increased.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  12. Absolute Values of Red Blood Cell Count

    Blood samples were collected at indicated time points for analysis of red blood cell count.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  13. Change From Baseline in Reticulocyte Count

    Blood samples were collected to assess reticulocyte count. Baseline was defined as mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated reticulocyte count increased.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  14. Absolute Values of Reticulocyte Count

    Blood samples were collected at indicated time points for analysis of reticulocyte count.

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20

  15. Percentage of Participants Who Received ESA Rescue

    Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

    Time frame: Up to 20 Weeks

  16. Mean Number of ESA Rescue Doses Administered Per Participant

    Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

    Time frame: Up to 20 Weeks

  17. Percentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue

    Participants were administered packed red blood cell transfusion as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia

    Time frame: Up to 20 Weeks

  18. Number of Packed Red Blood Cell Transfusion Administered Per Participant

    Participants were administered packed red blood cells as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

    Time frame: Up to 20 Weeks

  19. Time to First Transfusion or ESA Rescue Medication Intake

    Rescue therapy was defined as red blood cell transfusion or ESA administration in participants meeting Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

    Time frame: Up to 20 Weeks

  20. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.

    Time frame: Up to 20 Weeks

  21. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

    Parameters assessed for laboratory values included hematology, serum chemistry, and urinalysis. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to 20 Weeks

  22. Number of Participants With Clinically Significant Changes From Baseline in Vital Signs

    Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to 20 Weeks

  23. Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.

    Time frame: Up to 20 Weeks

  24. Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings

    A Baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to 20 Weeks

Other outcomes

  1. Exploratory: Change From Baseline in Iron and Total Iron Binding Capacity (TIBC)

    Time frame: Baseline and up to Week 20

  2. Exploratory: Change From Baseline in Transferrin

    Time frame: Baseline and up to Week 20

  3. Exploratory: Change From Baseline in Transferrin Saturation

    Time frame: Baseline and up to Week 20

  4. Exploratory: Mean Weekly Dose of Intravenous Elemental Iron Administered

    Time frame: Baseline and up to Week 20

  5. Exploratory: Absolute Values of Iron and Total Iron Binding Capacity (TIBC)

    Time frame: Baseline and up to Week 20

  6. Exploratory: Absolute Values of Transferrin

    Time frame: Baseline and up to Week 20

  7. Exploratory: Absolute Values of Transferrin Saturation

    Time frame: Baseline and up to Week 20

  8. Exploratory: Absolute Values of Reticulocyte Hemoglobin Content

    Time frame: Baseline and up to Week 20

  9. Exploratory: Change From Baseline in Reticulocyte Hemoglobin Content

    Time frame: Baseline and up to Week 20

  10. Exploratory: Change From Baseline in Hemoglobin A1c

    Time frame: Baseline and up to Week 20

  11. Exploratory: Absolute Values of Hemoglobin A1c

    Time frame: Baseline and up to Week 20

  12. Exploratory: Absolute Values of Lipids

    Time frame: Baseline and up to Week 20

  13. Exploratory: Change From Baseline in Lipids

    Time frame: Baseline and up to Week 20

  14. Exploratory: Change From Baseline in Hepcidin

    Time frame: Baseline and up to Week 20

  15. Exploratory: Absolute Values of Hepcidin

    Time frame: Baseline and up to Week 20

  16. Exploratory: Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

    Time frame: Baseline and up to Week 20

  17. Exploratory: Absolute Values of Interleukin 6, Cystatin C, Intact Parathyroid Hormone, and Calcitonin

    Time frame: Baseline and up to Week 20

  18. Exploratory: Change From Baseline in Interleukin 6, Cystatin C, Intact Parathyroid Hormone, and Calcitonin

    Time frame: Baseline and up to Week 20

  19. Exploratory: Neurocognitive Functioning as a Measure

    Time frame: Baseline and up to Week 20

  20. Exploratory: Patient-Reported Outcome Measures

    Time frame: Baseline and up to Week 20

  21. Exploratory: Plasma Concentrations of Vadadustat and Its Glucuronide Metabolites

    Time frame: Baseline and up to Week 20

  22. Exploratory: Plasma Concentrations of Vadadustat and Its Glucuronide Metabolites

    Time frame: Baseline

07

Results

Posted Jul 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneVadadustatPlacebo
Started13872
Completed11263
Not completed269
Withdrew: Adverse event103
Withdrew: Worsening of ckd64
Withdrew: Withdrawal by subject50
Withdrew: Worsening of anemia10
Withdrew: Protocol violation01
Withdrew: Non- compliance10
Withdrew: Sponsor decision10
Withdrew: Lost to follow-up11
Withdrew: Other10

Outcome measures

PrimaryPercentage of Participants Achieving a Successful Hemoglobin Response

Hemoglobin (Hgb) response was defined as participants with mean Hgb ≥11.0 grams per deciliter (g/dL) (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving Erythropoiesis-Stimulating Agents (ESA) or transfusion.

Time frame:
Weeks 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Successful Hemoglobin Response
Percentage of participantsVadadustatPlacebo
Percentage of Participants Achieving a Successful Hemoglobin Response54.910.3
Statistical analysis
  • Vadadustat vs Placebo · Fisher Exact · p = =0.0001 · Odds ratio (or): 11.4739 · 95% CI 3.3505 to 39.2931
SecondaryPercentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study

Participants who have experienced an excursion in Hgb to ≥13.0 g/dL at any time during the study were considered as "failures". Data was presented for failures.

Time frame:
Up to 20 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study
Percentage of participantsVadadustatPlacebo
Percentage of Participants With Hemoglobin Value ≥13.0 g/dL at Any Time During the Study59.688.9
Statistical analysis
  • Vadadustat vs Placebo · Fisher Exact · p = <0.0001
SecondaryPercentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value

Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing). Analysis of this secondary outcome measure is a reanalysis of the primary outcome measure whereby the response was determined solely by the Hgb value and receiving rescue therapy did not make the participant a failure.

Time frame:
Weeks 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value
Percentage of participantsVadadustatPlacebo
Percentage of Participants Achieving a Successful Hemoglobin Response, Determined Solely Based on the Hemoglobin Value44.913.9
Statistical analysis
  • Vadadustat vs Placebo · Fisher Exact · p = <0.0001
SecondaryPercentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group

Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Treatment Naïve group, defined as participants who had never received treatment with an ESA and who had a screening Hgb level of ≤10.5 g/dL.

Time frame:
Weeks 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group
Percentage of participantsVadadustatPlacebo
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Treatment naïve Group507.9
SecondaryPercentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group

Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Previously Treated group, defined as participants who had previously received ≥1 dose of an ESA, had been off of ESA therapy for ≥11 weeks at the time of screening, and had a screening Hgb level of ≤10.5 g/dL.

Time frame:
Weeks 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group
Percentage of participantsVadadustatPlacebo
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Previously Treated Group41.519
Statistical analysis
  • Vadadustat vs Placebo · Fisher Exact · p = =0.0953
SecondaryPercentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group

Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Participants were assigned to 1 of 3 study groups based on their ESA status at the screening visit: Naïve, Previously Treated and Actively Treated. Analysis of this secondary outcome measure was performed in the ESA Actively Treated group, defined as participants who had been actively treated with an ESA for a minimum of 4 months before screening, had received at least 2 doses within the last 4 months, had received their last dose within 6 weeks before screening, and had a screening Hgb level ≥9.5 g/dL and ≤12.0 g/dL.

Time frame:
Weeks 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group
Percentage of participantsVadadustatPlacebo
Percentage of Participants Achieving a Successful Hemoglobin Response in ESA Actively Treated Group33.37.7
Statistical analysis
  • Vadadustat vs Placebo · Fisher Exact · p = =0.1238
SecondaryPercentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population

Hgb response was defined as participants with mean Hgb ≥11.0 g/dL (average of Weeks 19 and 20) or increase in Hgb by ≥ 1.2 g/dL (average of Weeks 19 and 20) over pre-dose average (average of the two Hgb values obtained prior to dosing) without receiving ESA or transfusion. Analysis of this secondary outcome measure was performed in the mITT population.

Time frame:
Weeks 19 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population
Percentage of participantsVadadustatPlacebo
Percentage of Participants Achieving a Successful Hemoglobin Response, Analyzed in mITT Population44.111.1
Statistical analysis
  • Vadadustat vs Placebo · Fisher Exact · p = <0.0001
SecondaryChange From Baseline in Hemoglobin

Blood samples were collected to assess Hgb. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hgb concentration increased.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin
g/dLVadadustatPlacebo
Baseline9.94 ± 0.8619.96 ± 0.790
Week 20.1 ± 0.756-0.22 ± 0.564
Week 40.39 ± 0.868-0.25 ± 0.679
Week 60.63 ± 1.059-0.41 ± 0.835
Week 80.69 ± 1.087-0.4 ± 0.878
Week 120.9 ± 1.066-0.2 ± 0.864
Week 160.76 ± 1.055-0.18 ± 0.963
Week 190.73 ± 1.063-0.16 ± 0.926
Week 200.88 ± 1.161-0.08 ± 0.933
Statistical analysis
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.0019
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
SecondaryAbsolute Values of Hemoglobin

Blood samples were collected at indicated time points for analysis of hemoglobin

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · g/dL
Absolute Values of Hemoglobin
g/dLVadadustatPlacebo
Baseline9.94 ± 0.8619.96 ± 0.79
Week 210.02 ± 0.9099.74 ± 0.714
Week 410.35 ± 0.9799.7 ± 0.733
Week 610.61 ± 0.9969.6 ± 0.758
Week 810.66 ± 0.9879.6 ± 0.848
Week 1210.87 ± 0.9589.82 ± 0.682
Week 1610.79 ± 0.8959.83 ± 0.841
Week 1910.74 ± 0.8819.93 ± 0.897
Week 2010.88 ± 1.0029.93 ± 0.859
SecondaryChange From Baseline in Hematocrit

Blood samples were collected to assess Hematocrit. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated Hematocrit concentration increased.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · Percentage of red blood cells in blood
Change From Baseline in Hematocrit
Percentage of red blood cells in bloodVadadustatPlacebo
Baseline30.4 ± 2.9630.3 ± 2.90
Week 20.8 ± 2.46-0.6 ± 1.97
Week 42 ± 2.87-0.5 ± 2.33
Week 62.5 ± 3.55-1 ± 2.87
Week 82.7 ± 3.44-1 ± 3.15
Week 123 ± 3.5-0.3 ± 2.95
Week 163.3 ± 3.48-0.1 ± 3.24
Week 193.1 ± 3.510 ± 3.19
Week 203 ± 3.80.1 ± 3.13
Statistical analysis
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
SecondaryAbsolute Values of Hematocrit

Blood samples were collected at indicated time points for analysis of Hematocrit.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · Percentage of red blood cells in blood
Absolute Values of Hematocrit
Percentage of red blood cells in bloodVadadustatPlacebo
Baseline30.4 ± 2.9630.3 ± 2.9
Week 231.2 ± 3.0629.7 ± 2.62
Week 432.4 ± 3.1729.7 ± 2.72
Week 633.1 ± 3.2129.4 ± 2.46
Week 833.2 ± 3.0529.3 ± 3.05
Week 1233.5 ± 3.1930.2 ± 2.05
Week 1634 ± 3.0230.3 ± 2.87
Week 1933.7 ± 2.8330.7 ± 2.83
Week 2033.6 ± 3.1930.4 ± 2.7
SecondaryChange From Baseline in Red Blood Cell Count

Blood samples were collected to assess red blood cell count. Baseline was defined as the mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated red blood cell count increased.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · 10^6 cells per microliter
Change From Baseline in Red Blood Cell Count
10^6 cells per microliterVadadustatPlacebo
Baseline3.38 ± 0.4023.34 ± 0.322
Week 20.02 ± 0.243-0.08 ± 0.212
Week 40.12 ± 0.277-0.08 ± 0.222
Week 60.18 ± 0.346-0.14 ± 0.276
Week 80.23 ± 0.351-0.14 ± 0.32
Week 120.3 ± 0.357-0.08 ± 0.29
Week 160.28 ± 0.363-0.06 ± 0.331
Week 190.26 ± 0.374-0.04 ± 0.319
Week 200.3 ± 0.411-0.01 ± 0.314
Statistical analysis
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.0031
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
SecondaryAbsolute Values of Red Blood Cell Count

Blood samples were collected at indicated time points for analysis of red blood cell count.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · 10^6 cells per microliter
Absolute Values of Red Blood Cell Count
10^6 cells per microliterVadadustatPlacebo
Baseline3.38 ± 0.4023.34 ± 0.322
Week 23.39 ± 0.4183.25 ± 0.321
Week 43.51 ± 0.4093.24 ± 0.317
Week 63.57 ± 0.4123.2 ± 0.321
Week 83.61 ± 0.4213.21 ± 0.377
Week 123.68 ± 0.4573.27 ± 0.295
Week 163.69 ± 0.443.29 ± 0.343
Week 193.67 ± 0.4153.32 ± 0.332
Week 203.7 ± 0.4533.33 ± 0.318
SecondaryChange From Baseline in Reticulocyte Count

Blood samples were collected to assess reticulocyte count. Baseline was defined as mean of two samples obtained prior to dosing (Screening and Baseline). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicated reticulocyte count increased.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · 10^6 cells per microliter
Change From Baseline in Reticulocyte Count
10^6 cells per microliterVadadustatPlacebo
Baseline2.12 ± 0.8581.97 ± 0.816
Week 20.61 ± 0.778-0.07 ± 0.532
Week 40.29 ± 0.6860.06 ± 0.485
Week 60.19 ± 0.7490.08 ± 0.549
Week 8-0.08 ± 0.7370.06 ± 0.665
Week 12-0.12 ± 0.7420.02 ± 0.639
Week 160.03 ± 0.678-0.03 ± 0.659
Week 190.07 ± 0.88-0.05 ± 0.672
Week 200.03 ± 0.6660.12 ± 0.786
Statistical analysis
  • Vadadustat vs Placebo · t-test, 2 sided · p = <0.0001
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.0133
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.3053
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.1918
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.2090
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.6184
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.3604
  • Vadadustat vs Placebo · t-test, 2 sided · p = =0.4056
SecondaryAbsolute Values of Reticulocyte Count

Blood samples were collected at indicated time points for analysis of reticulocyte count.

Time frame:
Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 19 and Week 20
Reported as:
Mean · 10^6 cells per microliter
Absolute Values of Reticulocyte Count
10^6 cells per microliterVadadustatPlacebo
Baseline2.12 ± 0.8581.97 ± 0.816
Week 22.74 ± 1.0691.91 ± 0.727
Week 42.44 ± 0.9622.06 ± 0.731
Week 62.32 ± 0.9962.07 ± 0.897
Week 82.05 ± 0.8842.09 ± 0.85
Week 122.02 ± 0.9592 ± 0.846
Week 162.13 ± 0.9921.96 ± 0.83
Week 192.21 ± 1.2971.92 ± 0.77
Week 202.17 ± 0.9542.1 ± 0.88
SecondaryPercentage of Participants Who Received ESA Rescue

Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

Time frame:
Up to 20 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received ESA Rescue
Percentage of participantsVadadustatPlacebo
Epoetin Alfa4.412.5
Darbepoetin Alfa04.2
SecondaryMean Number of ESA Rescue Doses Administered Per Participant

Participants were administered epoetin alfa or darbepoetin alfa as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

Time frame:
Up to 20 Weeks
Reported as:
Mean · Doses/participants
Mean Number of ESA Rescue Doses Administered Per Participant
Doses/participantsVadadustatPlacebo
Epoetin Alfa1.7 ± 1.632.8 ± 1.79
Darbepoetin Alfa—4.3 ± 2.52
SecondaryPercentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue

Participants were administered packed red blood cell transfusion as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia

Time frame:
Up to 20 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue
Percentage of participantsVadadustatPlacebo
Percentage of Participants Who Received Packed Red Blood Cell Transfusion Rescue01.4
SecondaryNumber of Packed Red Blood Cell Transfusion Administered Per Participant

Participants were administered packed red blood cells as a rescue medication who have met the Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

Time frame:
Up to 20 Weeks
Reported as:
Median · Units of blood per participant
Number of Packed Red Blood Cell Transfusion Administered Per Participant
Units of blood per participantVadadustatPlacebo
Number of Packed Red Blood Cell Transfusion Administered Per Participant—1.0 (1 to 1)
SecondaryTime to First Transfusion or ESA Rescue Medication Intake

Rescue therapy was defined as red blood cell transfusion or ESA administration in participants meeting Hgb rescue criteria in addition to having experienced a clinically significant worsening of their anemia or the symptoms of anemia.

Time frame:
Up to 20 Weeks
Reported as:
Mean · Weeks
Time to First Transfusion or ESA Rescue Medication Intake
WeeksVadadustatPlacebo
Time to First Transfusion or ESA Rescue Medication Intake21.6 ± 6.0821.2 ± 5.71
Statistical analysis
  • Vadadustat vs Placebo · Log Rank · p = =0.0017 · Hazard ratio (hr): 4.1451 · 95% CI 1.5752 to 10.9080
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)

An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.

Time frame:
Up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsVadadustatPlacebo
TEAEs5829
Treatment-emergent SAEs3311
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

Parameters assessed for laboratory values included hematology, serum chemistry, and urinalysis. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
ParticipantsVadadustatPlacebo
Hematology00
Serum chemistry10
Urinalysis00
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Signs

Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
ParticipantsVadadustatPlacebo
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs00
SecondaryNumber of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.

Time frame:
Up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings
ParticipantsVadadustatPlacebo
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings10
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings

A Baseline physical examination was performed at screening. Otherwise, abbreviated physical examinations were conducted and were to include heart, lung, and abdomen. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings
ParticipantsVadadustatPlacebo
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings00
Other pre-specifiedExploratory: Change From Baseline in Iron and Total Iron Binding Capacity (TIBC)
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Transferrin
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Transferrin Saturation
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Mean Weekly Dose of Intravenous Elemental Iron Administered
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Iron and Total Iron Binding Capacity (TIBC)
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Transferrin
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Transferrin Saturation
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Reticulocyte Hemoglobin Content
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Reticulocyte Hemoglobin Content
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Hemoglobin A1c
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Hemoglobin A1c
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Lipids
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Lipids
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Hepcidin
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Hepcidin
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Absolute Values of Interleukin 6, Cystatin C, Intact Parathyroid Hormone, and Calcitonin
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Change From Baseline in Interleukin 6, Cystatin C, Intact Parathyroid Hormone, and Calcitonin
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Neurocognitive Functioning as a Measure
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Patient-Reported Outcome Measures
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Plasma Concentrations of Vadadustat and Its Glucuronide Metabolites
Time frame:
Baseline and up to Week 20

Results for this outcome have not been posted.

Other pre-specifiedExploratory: Plasma Concentrations of Vadadustat and Its Glucuronide Metabolites
Time frame:
Baseline

Results for this outcome have not been posted.

Adverse events

Collected over From the start of treatment (Day 1) up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat3/138 (2.2%)33/138 (23.9%)58/138 (42%)
Placebo0/72 (0%)11/72 (15.3%)29/72 (40.3%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventVadadustatPlacebo
RENAL FAILURE ACUTERenal and urinary disorders7/1382/72
RENAL FAILURE CHRONICRenal and urinary disorders6/1380/72
PNEUMONIAInfections and infestations2/1381/72
FLUID OVERLOADMetabolism and nutrition disorders2/1381/72
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders2/1380/72
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/1381/72
IRRITABLE BOWEL SYNDROMEGastrointestinal disorders0/1381/72
CRYPTOSPORIDIOSIS INFECTIONInfections and infestations0/1381/72
GASTROENTERITISInfections and infestations0/1381/72
OSTEOMYELITISInfections and infestations0/1381/72
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVadadustatPlacebo
DiarrhoeaGastrointestinal disorders14/1383/72
NauseaGastrointestinal disorders14/1383/72
Oedema peripheralGeneral disorders10/1387/72
Urinary tract infectionInfections and infestations8/1386/72
FatigueGeneral disorders11/1385/72
HypertensionVascular disorders11/1382/72
Upper Respiratory Tract InfectionInfections and infestations2/1385/72
HeadacheNervous system disorders8/1382/72
ConstipationGastrointestinal disorders5/1384/72
HypotensionVascular disorders6/1384/72

Baseline characteristics

Intent-to-Treat (ITT) Population: participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)VadadustatPlaceboTotal
Mean66.6 ± 9.9765.9 ± 12.3366.4 ± 10.81
Sex: Female, Male
Sex: Female, Male(Participants)VadadustatPlaceboTotal
Female8134115
Male573895
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VadadustatPlaceboTotal
American Indian or Alaska Native314
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American491968
White8349132
More than one race000
Unknown or Not Reported101
08

Study locations

47 sites
  • Glendale, Arizona, United States
  • Tucson, Arizona, United States
  • Azusa, California, United States
  • Chula Vista, California, United States
  • Downey, California, United States
  • El Centro, California, United States
  • La Mesa, California, United States
  • Long Beach, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Arvada, Colorado, United States
  • Westminster, Colorado, United States
  • Lauderdale Lakes, Florida, United States
  • Port Charlotte, Florida, United States
  • Tampa, Florida, United States
  • Augusta, Georgia, United States
  • Macon, Georgia, United States
  • Meridian, Idaho, United States
  • Evergreen Park, Illinois, United States
  • Lafayette, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Detroit, Michigan, United States
  • Lansing, Michigan, United States
  • Petoskey, Michigan, United States
  • Pontiac, Michigan, United States
  • Farmington, Missouri, United States
  • Kansas City, Missouri, United States
  • Las Vegas, Nevada, United States
  • Albuquerque, New Mexico, United States
  • Flushing, New York, United States
  • Mineola, New York, United States
  • New Rochelle, New York, United States
  • Rosedale, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Rocky Mount, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Columbia, South Carolina, United States
  • Knoxville, Tennessee, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Edinburg, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Saint George, Utah, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90(5):1115-1122. doi: 10.1016/j.kint.2016.07.019. Epub 2016 Sep 17. PubMed 27650732 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Sep 2014, 13 months.

Results were first posted in Jul 2022, 7 years 9 months after primary completion. A results delay was requested in Nov 2014.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 13 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2013
First posted
Jul 24, 2013
StartActual
Jul 23, 2013
Primary completionActual
Sep 3, 2014
CompletionActual
Sep 3, 2014
Results delay requested
Nov 12, 2014
Results first posted
Jul 1, 2022
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01906489
Responsible party
Sponsor
First posted
Jul 24, 2013
Start date
Jul 23, 2013
Primary completion
Sep 3, 2014
Completion
Sep 3, 2014
Results posted
Jul 1, 2022
Last update
Jul 21, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion